Clinical Trials
20 trialsNCT05099848 2026-05-22
A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
Phase 2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT05517239 2022-08-26
PEACH
Yonsei University
Phase 2 Completed
NCT02716766 2020-04-10
Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)
The University of Hong Kong
Phase 2 Completed
NCT03578874 2020-04-09
SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC
The University of Hong Kong
Phase 2 Completed
NCT02774187 2019-12-05
Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC
Sun Yat-sen University
Phase 3 Completed
NCT00941655 2019-11-13
Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT00941967 2019-07-10
Sorafenib With or Without Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Completed
NCT02069041 2018-11-21
A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02089633 2017-07-28
PACOX
Bio-Cancer Treatment International Limited
Phase 2 Completed
NCT00483405 2017-07-12
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00861783 2017-06-23
Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma
Traws Pharma, Inc.
Phase 1 Completed
NCT01313377 2017-01-25
Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery
UNICANCER
Phase 3 Completed
NCT00142467 2014-03-18
Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma
Massachusetts General Hospital
Phase 2 Completed
NCT00003427 2013-06-26
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00052364 2013-06-18
Oxaliplatin in Treating Patients With Liver Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00559455 2011-06-28
Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma
Sanofi
Phase 2 Completed
NCT00005860 2011-04-26
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
National Cancer Institute (NCI)
Phase 1 Completed
NCT00471965 2010-09-20
EACH
Sanofi
Phase 3 Completed
NCT00280618 2009-09-15
Oxaliplatin in Unresectable Hepatocellular Carcinoma
Sanofi
Phase 2 Completed